Supplemental File: Non-cutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy
Published: 16 December 2022| Version 1 | DOI: 10.17632/mrdyhdh78k.1
Contributors:
Maria Asdourian, Ted Jacoby, Nishi Shah, Tracey Otto, Leah Thompson, Edward Christopher Dee, Kerry Reynolds, Yevgeniy Semenov, Steven ChenDescription
This file includes additional details on study methodology and supplemental figures (Kaplan-Meier curves).
Files
Categories
Dermatology, Cancer Immunotherapy, Drug Adverse Reactions, Survival Analysis, Medical Oncology